PATHOPHYSIOLOGICAL CHARACTERISTICS OF THE HEMOSTASIS SYSTEM IN MECHANICAL JAUNDICE
Ingestion: chronic damage to liver tissue, narrowing of the bile ducts, or parenchymal liver diseases can be accompanied by pathologies of the hemostasis system. The mechanisms affecting hemostasis in mechanical jaundice can be considered from four perspectives: the first refers to vitamin K deficiency in mechanical jaundice, the second describes the effect of ongoing fibrosis and cirrhosis of the liver on hemostasis, the third analyzes the relationship between infectious-septic mechanisms and the hemostasis system, its clinical significance in patients with obstructive jaundice, and the latter includes the analysis of specific factors.
Understanding the pathophysiology of hemostatic changes in patients with cholestasis and often liver disease is the key to accurate diagnosis and treatment. Combining good knowledge with a thorough examination of each patient can lead to the most promising result
The purpose of the study: to study the literature on homeostasis in patients with mechanical jaundice.
Search strategy: in order to systematically search for scientific information and achieve the goal, scientific analysis of publications in the database of evidence-based medicine (pabmed) was carried out from 2005 to 2020 using specialized search engines (Google Academy) and electronic scientific libraries (Cyberleninka, address electronic Biblioteca). Inclusion criteria: research of high methodological quality: meta-analysis, systematic review and cohort studies, as well as publications in English and Russian with clearly formulated and statistically proven conclusions. Criteria for publication: summary of reports, messages in the form of abstracts, advertising articles.
Results: the mechanisms affecting hemostasis in mechanical jaundice can be considered from four perspectives: the first relates to vitamin K deficiency in mechanical jaundice, the second describes the effect of ongoing fibrosis and cirrhosis of the liver on hemostasis, the third analyzes the relationship between infectious-septic mechanisms and the hemostasis system, its clinical significance in patients with obstructive jaundice, and the latter includes the analysis of specific factors
Conclusion: hemostasis disorders in a patient with mechanical jaundice are multi-factorial and difficult to assess. The general rule is that the patient should be treated by a doctor, not by the results of laboratory tests. The information obtained through coagulation tests should be carefully studied and interpreted in clinical practice.
Meruert T. Orazgalieva1, https://orcid.org/0000-0002-9899-9881
Meyrbek J. Aimagambetov1, https://orcid.org/0000-0003-4699-8200
Nazarbek B. Omarov1, http://orcid.org/0000-0002-6201-8263
Moldir M. Akbaeva1, https://orcid.org/0000-0002-3616-7000
1 NJSC “Semey Medical University”, Semey, Republic of Kazakhstan.
1. Adam E.H., Möhlmann M., Herrmann E., Schneider S., Zacharowski K., Zeuzem S., Weber C.F., Weiler N. Assessment of hemostatic profile in patients with mild to advanced liver cirrhosis // World J Gastroenterol. 2020 May 7;26(17):2097-2110. doi: 10.3748/wjg.v26.i17.2097.
2. Agarwal B., Wright G., Gatt A., Riddell A., Vemala V., Mallett S., Chowdary P., Davenport A., Jalan R., Burroughs A. Evaluation of coagulation abnormalities in acute liver failure // J Hepatol. 2012 Oct;57(4):780-6. doi: 10.1016/j.jhep.2012.06.020.
3. Arroyo V., Moreau R., Kamath P.S., Jalan R., Ginès P., Nevens F., Fernández J., To U., García-Tsao G., Schnabl B. Acute-on-chronic liver failure in cirrhosis // Nat Rev Dis Primers. 2016 Jun 9;2:16041. doi: 10.1038/nrdp.2016.41.
4. Assis D.N. Chronic Complications of Cholestasis: Evaluation and Management // Clin Liver Dis. 2018 Aug;22(3):533-544.
5. Barton C.A. Treatment of Coagulopathy Related to Hepatic Insufficiency // Crit Care Med. 2016 Oct;44(10):1927-33. doi: 10.1097/CCM.0000000000001998.
6. Beckingham I.J., Ryder S.D. ABC of diseases of liver, pancreas,and biliary system: Investigation of liver and biliary disease // BMJ 2011;322:33-36.
7. Bitto N., Liguori E., La Mura V. Coagulation, Microenvironment and Liver Fibrosis // Cells. 2018 Jul 24;7(8):85. doi: 10.3390/cells7080085.
8. Blasi A. Coagulopathy in liver disease: Lack of an assessment tool // World J Gastroenterol. 2015 Sep 21;21(35):10062-71. doi: 10.3748/wjg.v21.i35.10062.
9. Bosch J., Reverter J.C. The coagulopathy in cirrhosis: Myth or reality? // Hepatology 2005;41:434-435.
10. Chapin J.C., Hajjar K.A. Fibrinolysis and the control of blood coagulation // Blood Rev. 2015 Jan;29(1):17-24. doi: 10.1016/j.blre.2014.09.003.
11. Chiang J.Y.L., Ferrell J.M. Bile Acid Metabolism in Liver Pathobiology // Gene Expr. 2018 May 18;18(2):71-87. doi: 10.3727/105221618X15156018385515.
12. Cimmino G., Ciccarelli G., Golino P. Role of Tissue Factor in the Coagulation Network // Semin Thromb Hemost. 2015 Oct;41(7):708-17. doi: 10.1055/s-0035-1564045.
13. Deutsch M., Koskinas J. Antiplatelets and Antithrombotics in Patients with Liver Insufficiency: From Pathophysiology to Clinical Practice // Curr Pharm Des. 2017. 23(9): 1346-1353. doi: 10.2174/1381612822666161205113629.
14. Daly M.E. Transcription factor defects causing platelet disorders // Blood Rev. 2017 Jan;31(1):1-10.
15. de Almeida J.P., Liberatti L.S., Barros F.E., Kallaur A.P., Lozovoy M.A., Scavuzzi B.M., Panis C., Reiche E.M., Dichi I., Simão A.N. Profile of oxidative stress markers is dependent on vitamin D levels in patients with chronic hepatitis C // Nutrition. 2016 Mar;32(3):362-7. doi: 10.1016/j.nut.2015.09.016.
16. Dillon A., Egan K., Kevane B., Galvin Z., Maguire P., Ní Áinle F., Stewart S. Liver stiffness and thrombin generation in compensated cirrhosis // Res Pract Thromb Haemost. 2019 Jan 28;3(2):291-297. doi: 10.1002/rth2.12173.
17. Eden RE, Coviello JM. Vitamin K Deficiency. 2020 Nov 21. In: StatPearls [Internet] // Treasure Island (FL): StatPearls Publishing; 2021 Jan–.
18. Federico A, Dallio M, Caprio GG, Ormando VM, Loguercio C. Gut microbiota and the liver // Minerva Gastroenterol Dietol. 2017 Dec;63(4):385-398. doi: 10.23736/S1121-421X.17.02375-3.
19. Gando S, Levi M, Toh CH. Disseminated intravascular coagulation // Nat Rev Dis Primers. 2016 Jun 2;2:16037. doi: 10.1038/nrdp.2016.37.
20. Giannini EG, Peck-Radosavljevic M. Platelet Dysfunction: Status of Thrombopoietin in Thrombocytopenia Associated with Chronic Liver Failure // Semin Thromb Hemost. 2015 Jul;41(5):455-61. doi: 10.1055/s-0035-1550432.
21. González-Reimers E, Quintero-Platt G, Martín-González C, Pérez-Hernández O, Romero-Acevedo L, Santolaria-Fernández F. Thrombin activation and liver inflammation in advanced hepatitis C virus infection // World J Gastroenterol. 2016 May 14;22(18):4427-37. doi: 10.3748/wjg.v22.i18.4427.
22. Green R. Vitamin B12 deficiency from the perspective of a practicing hematologist // Blood. 2017 May 11;129(19):2603-2611.
23. Hartmann M, Szalai C, Saner FH. Hemostasis in liver transplantation: Pathophysiology, monitoring, and treatment // World J Gastroenterol. 2016 Jan 28;22(4):1541-50. doi: 10.3748/wjg.v22.i4.1541.
24. Hajji SE, Balaphas A, Toso C, Gonelle-Gispert C, Bühler L, Meyer J. Preoperative platelet count does not predict the occurrence of post-hepatectomy liver failure after partial hepatectomy in a retrospective monocentric cohort study // Medicine (Baltimore). 2021 Feb 12;100(6):e24425. doi: 10.1097/MD.0000000000024425.
25. Helmke S, Colmenero J, Everson GT. Noninvasive assessment of liver function // Curr Opin Gastroenterol. 2015 May 31(3), 199-208. doi: 10.1097/MOG.0000000000000167.
26. Huang RX, Wang BC, Fan JG. Research advances of relationship between non-alcoholic fatty liver disease and biliary tract diseases/ //. Zhonghua Gan Zang Bing Za Zhi. 2017 Aug 20;25(8):633-636.
27. Iqbal U, Dennis BB, Li AA, Cholankeril G, Kim D, Khan MA, Ahmed A. Use of anti-platelet agents in the prevention of hepatic fibrosis in patients at risk for chronic liver disease: a systematic review and meta-analysis // Hepatol Int. 2019 Jan;13(1):84-90. doi: 10.1007/s12072-018-9918-2.
28. Koch A., Trautwein C., Tacke F. Acute liver failure. // Gastroenterologe. 2017. 12(6):507-517. doi: 10.1007/s11377-017-0214-9.
29. King R.J., Ajjan R.A. Vascular risk in obesity: Facts, misconceptions and the unknown // Diab Vasc Dis Res. 2017 Jan. 14(1):2-13. doi: 10.1177/1479164116675488.
30. Kurokawa T., Ohkohchi N. Platelets in liver disease, cancer and regeneration // World J Gastroenterol. 2017 May 14;23(18):3228-3239. doi: 10.3748/wjg.v23.i18.3228.
31. Levi M., van der Poll T. Coagulation and sepsis // Thromb Res. 2017 Jan;149:38-44. doi: 10.1016/j.thromres.2016.11.007.
32. Leebeek F.W., Rijken D.C. The Fibrinolytic Status in Liver Diseases // Semin Thromb Hemost. 2015 Jul;41(5):474-80. doi: 10.1055/s-0035-1550437.
33. Liu P, Hum J, Jou J, Scanlan RM, Shatzel J. Transfusion strategies in patients with cirrhosis // Eur J Haematol. 2020 Jan;104(1):15-25. doi: 10.1111/ejh.13342.
34. Mackavey CL, Hanks R. Hemostasis, coagulation abnormalities, and liver disease // Crit Care Nurs Clin North Am. 2013 Dec;25(4):435-46, v. doi: 10.1016/j.ccell.2013.09.001.
35. Margaritis P. Gene-based continuous expression of FVIIa for the treatment of hemophilia // Front Biosci (Schol Ed). 2012 Jan 1;4:287-99. doi: 10.2741/269.
36. Matsui T., Hori A., J Hamako, F Matsushita, Y Ozeki, Y Sakurai, M Hayakawa, M Matsumoto, Y Fujimura. Mutant botrocetin-2 inhibits von Willebrand factor-induced platelet agglutination // J Thromb Haemost. 2017 Mar;15(3):538-548.
37. McCarty OJ, Calaminus SD, Berndt MC, Machesky LM, Watson SP. von Willebrand factor mediates platelet spreading through glycoprotein Ib and alpha(IIb)beta3 in the presence of botrocetin and ristocetin, respectively // J Thromb Haemost. 2006 Jun;4(6):1367-78.
38. Milosevic I, Vujovic A, Barac A, Djelic M, Korac M, Radovanovic Spurnic A, Gmizic I, Stevanovic O, Djordjevic V, Lekic N, Russo E, Amedei A. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature // Int J Mol Sci. 2019 Jan 17;20(2):395. doi: 10.3390/ijms20020395.
39. Moole H., Bechtold M., Puli S.R. Efficacy of preoperative biliary drainage in malignant obstructive jaundice: a meta-analysis and systematic review // World J Surg Oncol. 2016 Jul 11;14(1):182. doi: 10.1186/s12957-016-0933-2.
40. Morita N., Nakahara K., Morita R., Suetani K., Michikawa Y., Sato J., Tsuji K., Ikeda H., Matsunaga K., Watanabe T., Matsumoto N., Okuse C., Suzuki M., Itoh F. Efficacy of Combined Thrombomodulin and Antithrombin in Anticoagulant Therapy for Acute Cholangitis-induced Disseminated Intravascular Coagulation // Intern Med. 2019 Apr 1;58(7):907-914.
41. Navaneethan U., Jayanthi V., Mohan P. Pathogenesis of cholangitis in obstructive jaundice-revisited // Minerva Gastroenterol Dietol. 2011 Mar;57(1):97-104.
42. Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease // Liver Int. 2017 Jun;37(6):778-793. doi: 10.1111/liv.13317.
43. Pieri G., Theocharidou E., Burroughs A.K. Liver in haematological disorders. Best Pract Res Clin Gastroenterol. 2013 Aug;27(4):513-30. doi: 10.1016/j.bpg.2013.06.012.
44. Ramadori P., Klag T., Malek N.P., Heikenwalder M. Platelets in chronic liver disease, from bench to bedside. JHEP Rep. 2019 Oct 25;1(6):448-459. doi: 10.1016/j.jhepr.2019.10.001.
45. Rautou P.E., Vion A.C., Luyendyk J.P., Mackman N. Circulating microparticle tissue factor activity is increased in patients with cirrhosis // Hepatology. 2014 Nov;60(5):1793-5. doi: 10.1002/hep.27033.
46. Reasor D.A., Mehrabadi M., Ku D.N., Aidun C.K. Determination of critical parameters in platelet margination // Ann Biomed Eng. 2013 Feb;41(2):238-49.
47. Rosenqvist K., Eriksson L.G., Rorsman F., Sangfelt P., Nyman R. Endovascular treatment of acute and chronic portal vein thrombosis in patients with cirrhotic and non-cirrhotic liver // Acta Radiol. 2016 May;57(5):572-9.
48. Rovegno M, Vera M, Ruiz A, Benítez C. Current concepts in acute liver failure. Ann Hepatol. 2019 Jul-Aug;18(4):543-552. doi: 10.1016/j.aohep.2019.04.008.
49. Royston D. The current place of aprotinin in the management of bleeding // Anaesthesia. 2015 Jan;70 Suppl 1:46-9.
50. Saja MF, Abdo AA, Sanai FM, Shaikh SA, Gader AG. The coagulopathy of liver disease: does vitamin K help? // Blood Coagul Fibrinolysis. 2013 Jan;24(1):10-7. doi: 10.1097/MBC.0b013e32835975ed.
51. Schulman S., El-Darzi E., Florido M.H., Friesen M., Merrill-Skoloff G., Brake M.A., Schuster C.R., Lin L., Westrick R.J., Cowan C.A., Flaumenhaft R. A coagulation defect arising from heterozygous premature termination of tissue factor // J Clin Invest. 2020 Oct 1;130(10):5302-5312. doi: 10.1172/JCI133780.
52. Semela D. Systemic disease associated with noncirrhotic portal hypertension // Clin Liver Dis (Hoboken). 2015 Oct 28;6(4):103-106.
53. Smith N.L., Heit J.A., Tang W., Teichert M., Chasman D.I., Morange P.E. Venous Thrombosis Genetic Replication Consortium. Genetic variation in F3 (tissue factor) and the risk of incident venous thrombosis: meta-analysis of eight studies // J Thromb Haemost. 2012 Apr;10(4):719-22. doi: 10.1111/j.1538-7836.2012.04665.x.
54. Sookoian S., Pirola CJ. Liver enzymes, metabolomics and genome-wide association studies: from systems biology to the personalized medicine // World J Gastroenterol. 2015 Jan 21;21(3):711-25. doi: 10.3748/wjg.v21.i3.711.
55. Smolenski A. Novel roles of cAMP/cGMP-dependent signaling in platelets // J Thromb Haemost. 2012 Feb;10(2):167-76.
56. Stravitz R.T., Ellerbe C., Durkalski V., Schilsky M., Fontana R.J., Peterseim C., Lee W.M. Acute Liver Failure Study Group // Bleeding complications in acute liver failure. Hepatology. 2018 May;67(5):1931-1942. doi: 10.1002/hep.29694.
57. Strople J., Lovell G., Heubi J. Prevalence of subclinical vitamin K deficiency in cholestatic liver disease // J Pediatr Gastroenterol Nutr. 2009 Jul.49(1):78-84.
58. Shay R., Taber D., Pilch N., Meadows H., Tischer S., McGillicuddy J., Bratton C., Baliga P., Chavin K. Early aspirin therapy may reduce hepatic artery thrombosis in liver transplantation // Transplant Proc. 2013 Jan-Feb;45(1):330-4. doi: 10.1016/j.transproceed.2012.05.075.
59.Uitte de Willige S., Malfliet J.J., Janssen H.L., Leebeek F.W., Rijken D.C. Increased N-terminal cleavage of alpha-2-antiplasmin in patients with liver cirrhosis // J Thromb Haemost. 2013 Nov;11(11):2029-36.
60. Valla D.C., Rautou P.E. The coagulation system in patients with end-stage liver disease // Liver Int. 2015 Jan;35 Suppl 1:139-44. doi: 10.1111/liv.12723.
61. van der Meer A.J., Scicluna B.P., Moerland P.D., Lin J., Jacobson E.W., Vlasuk G.P., van der Poll T. The Selective Sirtuin 1 Activator SRT2104 Reduces Endotoxin-Induced Cytokine Release and Coagulation Activation in Humans // Crit Care Med. 2015 Jun;43(6):e199-202. doi: 10.1097/CCM.0000000000000949.
62. Wagener G., Bakker J. Vasopressin in cirrhosis and sepsis: physiology and clinical implications // Minerva Anestesiol. 2015 Dec;81(12):1377-83.
63. Wu R., Wang N., Comish P.B., Tang D., Kang R. Inflammasome-Dependent Coagulation Activation in Sepsis // Front Immunol. 2021 Mar 16;12:641750. doi: 10.3389/fimmu.2021.641750.
64. Yang X, Cheng X, Tang Y, Qiu X, Wang Y, Kang H, Wu J. et al. Bacterial Endotoxin Activates the Coagulation Cascade through Gasdermin D-Dependent Phosphatidylserine Exposure // Immunity. 2019 Dec 17;51(6):983-996.e6. doi: 10.1016/j.immuni.2019.11.005.
65. Youngwon N., Kim J.E., Lim H.S., Han K.S. Kim H.K.. Coagulation proteins influencing global coagulation assays in cirrhosis: hypercoagulability in cirrhosis assessed by thrombomodulin-induced thrombin generation assay // Biomed Res Int. 2013;2013:856754. doi: 10.1155/2013/856754.
66. Zhang Y.M., Yu W., Zhou N., Li J.Z., Xu L.C., Xie Z.Y., Lu Y.F., Li L.J.. High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid. Hepatobiliary Pancreat Dis Int. 2015 Jun;14(3):287-92. doi: 10.1016/s1499-3872(15)60379-4.
67. Zermatten M.G., Fraga M., Calderara D.B., Aliotta A., Moradpour D., Alberio L. Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis // JHEP Rep. 2020 May 11;2(4):100120. doi: 10.1016/j.jhepr.2020.100120.
Number of Views: 108
Category of articles:
Reviews
Bibliography link
Orazgalieva M.T., Aimagambetov M.J., Omarov N.B., Akbaeva M.M. Pathophysiological characteristics of the hemostasis system in mechanical jaundice // Nauka i Zdravookhranenie [Science & Healthcare]. 2022, (Vol.24) 3, pp. 194-203. doi 10.34689/SH.2022.24.3.022Related publications:
INTERRELATION OF INTRAABDOMINAL HYPERTENSION AND MARKERS OF GASTROINTESTINAL TRACT INJURY IN PATIENTS WITH MULTIORGAN DYSFUNCTION
DRUG-INDUCED LIVER INJURY AND GENDER DIFFERENCES
QUALITY OF LIFE IN PRIMARY BILIARY CHOLANGITIS AND ITS ASSESSMENT
DIAGNOSTIC AND THERAPEUTIC LAPAROSCOPY FOR ABDOMINAL INJURIES. REVIEW
METHODS FOR SCHOOL-AGE CHILDREN NUTRITIONAL STATUS ASSESSMENT: FOCUS ON ANTHROPOMETRIC PARAMETERS. A REVIEW.